Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by AKO Capital LLP

AKO Capital LLP lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 25.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 313,784 shares of the medical research company's stock after selling 109,689 shares during the quarter. Thermo Fisher Scientific makes up about 2.3% of AKO Capital LLP's portfolio, making the stock its 20th biggest holding. AKO Capital LLP owned approximately 0.08% of Thermo Fisher Scientific worth $163,240,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of TMO. Norges Bank purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at $3,149,754,000. Proficio Capital Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 68,617.0% in the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock valued at $396,810,000 after purchasing an additional 761,649 shares during the period. Raymond James Financial Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $377,901,000. Lindsell Train Ltd purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $211,858,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 15.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,810,128 shares of the medical research company's stock worth $1,461,913,000 after buying an additional 366,191 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 in the last three months. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 1.2 %

Shares of NYSE:TMO traded down $5.96 on Tuesday, hitting $491.64. 607,792 shares of the company's stock were exchanged, compared to its average volume of 1,913,491. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 1-year low of $484.27 and a 1-year high of $627.88. The company has a market capitalization of $185.48 billion, a PE ratio of 29.75, a P/E/G ratio of 2.99 and a beta of 0.79. The firm's 50-day moving average is $540.37 and its 200 day moving average is $551.02.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 10.41%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMO. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 31st. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Bank of America dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Raymond James reaffirmed an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $653.23.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.